Axsome's solriamfetol shows mixed results amid 13 phase III wins in April

May 27, 2025

BioWorld recorded 151 clinical trial updates from phases I through III in April 2025, a drop from 197 in March. The month saw 13 successful phase III readouts, alongside four failed trials and two with mixed results.

BioWorld Analysis and data insight Clinical

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Unmasking the X: EPAC2 shifts the fragile X landscape

BioWorld

Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...

Recludix presents STAT1/3 inhibitors for dermatological diseases

BioWorld Science

Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.